You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (90) |
Back to Search
Immune Checkpoint Inhibitor (ICI)-Induced Acute Hepatitis Complicated by Cytomegalovirus (CMV) Hepatitis
- At: Virtual 2020 (2020)
- Type: Poster
- Poster code: POS-HPS-041
- By: SHEN, Chuan-Kuo (Chang Gung Memorial Hospital, Pharmacy, China Taiwan)
- Co-author(s): Chuan-Kuo Shen: Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China
Chi-Yuan Cheng: Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China
Wen-Cheng Chang: Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China
Yi-Cheng Chen: Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China
Tzu-Cheng Tsai: Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China
Hui-Yu Chen: Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China
Shin-Tarng Deng: Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, Province of China - Abstract:
Background
"EN-US">"EN-US">Immune checkpoint inhibitors (ICIs) combination therapies are widely used in cancer treatment recently. One of the cons of drug combination strategies is hard to find the culprit drug once adverse drug events (ADEs) occur. We presented a case who developed acute hepatitis after receiving pembrolizumab plus lenvatinib.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026